Shailendra Tallapaka's Contact Details

Shailendra Tallapaka's Company Details

DILIsym Services, a Simulations Plus Company

N/A, NC, US • 20 - 49 Employees
BioTech/Drugs

DILIsym Services, Inc. has developed DILIsym® and NAFLDsym® QSP software, and is developing IPFsym™ and RENAsym™ QSP software, to provide the pharmaceutical industry with the tools and resources to efficiently develop safe and effective drug therapies. DILIsym and RENAsym are designed to address drug-induced liver injury (DILI) and drug-induced acute kidney injury, respectively. NAFLDsym and IPFsym are designed for target or compound evaluation of therapeutic efficacy in nonalcoholic fatty liver disease (NAFLD or NASH) and idiopathic pulmonary fibrosis (IPF), respectively. Thus, DILIsym and RENAsym may be applied to address drug safety across therapeutic areas, while NAFLDsym and IPFsym may be applied to support the development of efficacious drugs in these therapeutic areas. DILIsym Services, Inc. makes these tools available to small, mid-size and large pharmaceutical organizations and regulatory agencies through its licensing programs. In addition to performing consulting services using the modeling softwares, the expert scientific team engages clients from initial program design through data input and "results" interpretation. Our mission is to apply our modeling and simulation expertise to support the development of safe and efficacious drug therapies. We aim to make drug development more efficient for the pharmaceutical industry by informing critical decisions, which will, in turn, lead to an increased availability of vital medicines for the patients who need them. We also promote the advancement of drug safety sciences by making DILIsym software available to academic researchers at accredited academic institutions, and through the Simulations Plus Distinguished Site for M&S Advancement program.